Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial
Publication Type
Conference Paper
Year of Publication
2021
Authors
Kymes, Steven Scott, Ingrid U; Oden, Neal; VanVeldhuisen, Paul C; VanVeldhuisen, Paul C
Secondary
Association for Research in Vision and Ophthalmology Annual Meeting
Date Published
May/2021
Location
Virtual
Keywords
SCORE2
Abstract
SCORE2 demonstrated that, for visual acuity letter score (VALS) change, bevacizumab is non-inferior to aflibercept for treatment of macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO).
While bevacizumab was non-inferior, aflibercept had a numerical advantage in VALS letters gained.
The average cost for aflibercept is 10 times that of bevacizumab, but it is not known whether the increased VALS gained offsets this cost.